- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2019–2025 · research · R35
Data Analysis Tools for Emerging High-Throughput Technologies
Rafael Angel Irizarry · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damage
Elizabeth Harmon Stover · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R21
The role of Ig Polymorphism in shaping the Broadly Neutralizing Antibody Response to Hemagglutinin HA stem domain(s) of Influenza A, Group 1 and 2 Viruses
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R01
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis
Carl D Novina · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R01
Enrichment of the State-1 Conformation of the HIV-1 Envelope Glycoprotein
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Integration of early genetic alterations and inflammation in gastroesophageal premalignancy
Nilay Sethi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R35
The DREAM B-Myb-MuvB complex controls sensitivity to DNA replication activators and inhibitors
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · research · R01
Small molecules targeting hepatic glucose production and insulin resistance
Patrick Robert Griffin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Cellular and molecular characterization of the digestive tract sub-epithelium
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · cooperative agreement · UG1
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
Harold John Burstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Incomplete Penetrance via Edgetic Suppression
Michael A Calderwood · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Mechanistic Determinants of Follicular-Helper T-cell Lymphomagenesis
Samuel Yao-Ming Ng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
Thomas M Roberts · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Interface-resolution domain-domain interactome map of the yeast complexome
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
Thomas M Roberts · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R01
Enrichment of the State-1 Conformation of the HIV-1 Envelope Glycoprotein
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R56
CNS Viral Escape in HIV-infected Adults
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · grant · PCRP
Targeting EZH2 for Novel Combination Therapeutic Strategies in Aggressive Variant Prostate Cancer
Katherine Morel · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2021 · career development · K99
Direct whole-genome haplotype-resolved assembly using sequence graphs
Shilpa Garg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R35
Data Analysis Tools for Emerging High-Throughput Technologies
Rafael Angel Irizarry · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R01
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis
Carl D Novina · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · grant · OCRP
Stalled Replication Fork Protection Defects as a Predictor of Therapeutic Response
Sarah Hill · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2022 · fellowship · Pew Biomedical Scholars
Pew Biomedical Scholar: Philip Kranzusch (2019)
Philip Kranzusch · Dana-Farber Cancer Institute · funded by Pew Charitable Trusts
2019 · award
Mechanisms of electron transport chain supercomplex assembly during ER and nutrient stress
Pedro Latorre-Muro · Dana-Farber Cancer Institute · funded by Human Frontier Science Program
2019–2024 · career development · K08
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma
Eric L Smith · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · fellowship · F32
Elucidating the role of the SAGA complex in MYCN-amplified neuroblastoma
Clare Felicity Malone · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · fellowship · F32
Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer
Jason Kwon · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · fellowship · F32
Mismatch Repair Proteins as Drivers of Temozolomide Resistance in Glioblastoma
Adam Nathaniel Boynton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R01
Enrichment of the State-1 Conformation of the HIV-1 Envelope Glycoprotein
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · training · T32
Cancer Chemical Biology and Metabolism Training Program
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Deciphering the mechanism underlying BRCA1 breast cancer development
David Morse Livingston · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Informed Combination Strategies for Peripheral T-cell Lymphomas
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Immune Modulation After Allogeneic HCT
Robert Jon Soiffer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2020 · research · R03
Tools for the understudied kinase PNK3
Jarrod A. Marto · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · cooperative agreement · UG1
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
Harold John Burstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
